Resolution Bioscience

16 articles about Resolution Bioscience

• Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition

  6/28/2021

  Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute .

• 

  Agilent Adds Liquid Biopsy Assay to Diagnostic Tool Bag with $550 Million Buy

  3/2/2021

  If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.

• Resolution Bioscience and LabCorp Will Collaborate to Commercialize the Resolution ctDx Lung™ Liquid Biopsy Assay

  2/24/2020

  Feb. 24, 2020 13:00 UTC Resolution ctDx Lung assay has a demonstrated ability to provide clinically actionable results that can inform care decisions for NSCLC patients KIRKLAND, Wash.--( BUSINESS WIRE )-- Resolution Bioscience, Inc. , today announced an agreement with LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, to make the Resolution ctDx™ Lung assay available to clinicians and patients. The fast, accu

• Vanderbilt Oncologists Publish Results of First Study to Demonstrate Clinical Utility of Resolution Liquid Biopsy Assay to Monitor Response and Resistance to Ensartinib

  10/29/2019

  New Journal of Thoracic Oncology publication concludes prospective application of technology may translate to improved outcomes for non-small cell lung cancer patients

• Resolution Advancing Development of Cell-Free DNA Companion Diagnostic for Prostate Cancer through Collaboration with Janssen

  6/19/2019

  Liquid biopsy assay with recent Breakthrough Device Designation from FDA is being used to screen patients with prostate cancer for HRD mutations and deletions as part of phase II and III clinical studies

• Resolution Liquid Biopsy Assay Detects More Complex Variants than Guardant360 in Retrospective Lung Cancer Comparison Study

  6/17/2019

  Team led by scientists from Dana-Farber Cancer Institute publish results from non-small cell lung carcinoma study in scientific journal Lung Cancer

• Resolution Liquid Biopsy Assay Receives Breakthrough Device Designation from FDA

  5/30/2019

  Resolution Bioscience, Inc., today announced that the Resolution HRD™ liquid biopsy assay has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA).

• Resolution Liquid Biopsy Assay Demonstrates Fewer False Positives and Higher Positive Predictive Value Than Three Known Commercial ctDNA NGS Tests

  4/9/2019

  AstraZeneca scientists publish results of first blinded study to use replicate tumor-matched plasmas and multiple orthogonal assays to examine factors affecting tumor-plasma concordance

• Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pilot Study

  4/1/2019

  Scientists from Dana-Farber Cancer Institute present results demonstrating detection of more actionable oncogenic fusions today at AACR Annual Meeting

• Resolution Liquid Biopsy Assay Detects More Actionable Oncogenic Fusions With Higher Allele Frequency than Guardant360

  3/27/2019

  Resolution Bioscience, Inc. today announced that scientists from Dana-Farber Cancer Institute will be presenting the results of a liquid biopsy comparison study between Resolution’s ctDx-Lung assay and Guardant Health’s Guardant360 at the American Association for Cancer Research (AACR) Annual Meeting on March 29-April 3, 2019.

• Resolution Bioscience Earns New York State Approval for Blood-Based Lung Cancer Assay

  9/18/2018

  Resolution Bioscience's ctDx Lung cancer assay identifies actionable mutations in non-small cell lung cancer

• Resolution Bioscience Announces Collaboration On Liquid Biopsies

  9/7/2016

• Resolution Bioscience To Participate At The FDA-AACR Liquid Biopsy Workshop

  7/25/2016

• Resolution Bioscience To Participate At The FDA-AACR Liquid Biopsy Workshop

  7/14/2016

• Resolution Bioscience's ctDx Blood-Based NGS Platform Used For Plasma Genotyping And Longitudinal Monitoring Of ALK Fusion Positive Patients In Clinical Trial

  6/1/2016

• Resolution Bioscience Release: Liquid Biopsy Testing Underway With Seattle Lung Cancer Patients

  5/25/2016